Bad News Is Good News

Ironical as it may sound, ‘bad news has been good news’ for Sun Pharma, one of India’s leading pharmaceutical companies. While tabloids across the nation splashed headlines covering the aftermath of the Dengue carnage back in 2015, Sun Pharma lead from the front looking for a solution to terminate the menace that had cost the world $8.9 billion. The hard work payed off last Wednesday when the Pharma Giant joined hands with International Centre for Genetic Engineering in its quest to develop a botanical drug for the treatment of Dengue.

The Silver Lining

Cissampelos pariera or Cipa as its is famously known has the potential to terminate the spread of Dengue. A Sun Pharma spokes person was quoted saying that the company would develop Cipa adhering to drug registration procedures fulfilling all regulatory standards of India including in-vitro, in-vivo clinical studies. The one of a kind agreement gives Sun Pharma the power to access all intellectual properties of Cipa in as many as 17 countries across the world.

Dengue Takes A Toll

Back in 2015 Delhi registered 10683 cases of dengue, the worst of its kind in two decades. Sun Pharma converted the crisis into an opportunity. According to reports, India represents almost 50% of the global risk posed by dengue. The disease which causes very high virus load and reduces platelet counts is potentially fatal and causes hemorrhage thereby giving the company a big opportunity to dominate the global pharmaceutical space in its quest to eradicate dengue from the face of the earth.

The Sunny Side

Sun Pharma, the worlds fifth largest specialty generic pharmaceutical company runs on a vertically integrated business model backed by an extremely capable team that has the know how to deliver quality drugs in a timely order. It helps the company price its products within affordable range of its consumers. The company has its product base spread across 150 countries in the world while its manufacturing facilities are sprawled across 6 continents. Sun Pharma's Research and Development Centres dot the globe with a multicultural workforce consisting of 50 nationalities.

Profits From Pain

In the last 12 months ending on March 2015 Sun Pharma recorded a consolidated revenue of $4.5 billion.The United States has pumped almost $2.2 billion into the company’s revenue pie.The picture in India has been consistent with its global dominance even as the company boasts 30 of its products in the top 300 brands in the subcontinent. Sun Pharma has a compelling market share in Europe as well as the emerging economies. Its Global Consumer Healthcare Business is ranked amongst the top ten across four global markets. A company that fosters excellence through innovation and is supported by b R&D backed by 2000 odd scientists looks all set to bring about a new sun rise at a time when humanity is fighting a rigorous battle against the dengue nightmare.